Florey Department of Neuroscience and Mental Health - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/269

Filters

2020 - 2021 3
3
Reset filters

Settings
Statistics
Citations
Author: McLean, Catriona × Author: Masters, Colin × Author: Senesi, Matteo × Start date: 2020 × End date: 2022 ×

Search Results

Now showing 1 - 3 of 3
  • Item
    No Preview Available
    Erratum to: Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2020.
    Stehmann, C ; Senesi, M ; Sarros, S ; McGlade, A ; Lewis, V ; Simpson, M ; Klug, G ; McLean, C ; Masters, CL ; Collins, SJ (Australian Government Department of Health and Aged Care, 2021-08-09)
    Erratum to Commun Dis Intell (2018) 2021;45 (https://doi.org/10.33321/cdi.2021.45.38).
  • Item
    No Preview Available
    Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2020 (vol 22, 45, 2021)
    Stehmann, C ; Senesi, M ; Sarros, S ; McGlade, A ; Lewis, V ; Simpson, M ; Klug, G ; McLean, C ; Masters, CL ; Collins, S (AUSTRALIAN GOVERNMENT, DEPT HEALTH & AGEING, 2021-08-09)
    Nationwide surveillance of Creutzfeldt-Jakob disease and other human prion diseases is performed by the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). National surveillance encompasses the period since 1 January 1970, with prospective surveillance occurring from 1 October 1993. Over this prospective surveillance period, considerable developments have occurred in pre-mortem diagnostics; in the delineation of new disease subtypes; and in a heightened awareness of prion diseases in healthcare settings. Surveillance practices of the ANCJDR have evolved and adapted accordingly. This report summarises the activities of the ANCJDR during 2020. Since the ANCJDR began offering diagnostic cerebrospinal fluid (CSF) 14-3-3 protein testing in Australia in September 1997, the annual number of referrals has steadily increased. In 2020, 510 domestic CSF specimens were referred for 14-3-3 protein testing and 85 persons with suspected human prion disease were formally added to the national register. As of 31 December 2020, just over half (44 cases) of the 85 suspect case notifications remain classified as 'incomplete'; 27 cases were excluded through either detailed clinical follow-up (9 cases) or neuropathological examination (18 cases); 18 cases were classified as 'definite' and eleven as 'probable' prion disease. For 2020, sixty percent of all suspected human-prion-disease-related deaths in Australia underwent neuropathological examination. No cases of variant or iatrogenic CJD were identified. The SARS-CoV-2 pandemic did not affect prion disease surveillance outcomes in Australia.
  • Item
    No Preview Available
    Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December
    Stehmann, C ; Senesi, M ; Sarros, S ; McGlade, A ; Simpson, M ; Klug, G ; McLean, C ; Masters, CL ; Collins, S (AUSTRALIAN GOVERNMENT, DEPT HEALTH & AGEING, 2020-07-14)
    Nationwide surveillance of Creutzfeldt-Jakob disease and other human prion diseases is performed by the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). National surveillance encompasses the period since 1 January 1970, with prospective surveillance occurring from 1 October 1993. Over this prospective surveillance period, considerable developments have occurred in pre-mortem diagnostics; in the delineation of new disease subtypes; and in a heightened awareness of prion diseases in healthcare settings. Surveillance practices of the ANCJDR have evolved and adapted accordingly. This report summarises the activities of the ANCJDR during 2019. Since the ANCJDR began offering diagnostic cerebrospinal fluid (CSF) 14-3-3 protein testing in Australia in September 1997, the annual number of referrals has steadily increased. In 2019, 513 domestic CSF specimens were referred for 14-3-3 protein testing and 85 persons with suspected human prion disease were formally added to the national register. As of 31 December 2019, just under half (42 cases) of the 85 suspect case notifications remain classified as 'incomplete'; 16 cases were excluded through either detailed clinical follow-up (3 cases) or neuropathological examination (13 cases); 20 cases were classified as 'definite' and seven as 'probable' prion disease. For 2019, sixty-three percent of all suspected human prion disease related deaths in Australia underwent neuropathological examination. No cases of variant or iatrogenic CJD were identified. Two possibly causal novel prion protein gene (PRNP) sequence variations were identified.